Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018

Jean, Shio-Shin; Lee, Yu-Lin; Liu, Po‐Yu; Lu, Min-Chi; Ko, Wen–Chien; Hsueh, Po‐Ren

doi:10.1016/j.jmii.2021.07.015

Cited by 35 publications

(20 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the MDR rate of Taiwanese P. aeruginosa isolates was less than 18% before 2015. However, the 2016–2018 susceptibility survey of 1,127 P. aeruginosa isolates in Taiwan revealed a trend toward prominent escalation in the annual non-susceptible (NS) rates to anti-pseudomonal carbapenems (from 19.7% in 2016 to 27.5% in 2018 [ Figure 1 ]; 95% CI: 0.545–0.936; P = 0.016) ( Jean et al., 2021 ). When assessed using linear regression analysis, these results corresponded with the annual proportions of pneumonia-causing P. aeruginosa isolates ( r = 0.980, P = 0.127) ( Jean et al., 2021 ).…”

Section: Global Trends Of Carbapenem Resistance Among Important Gnb S...mentioning

confidence: 99%

“…However, the 2016–2018 susceptibility survey of 1,127 P. aeruginosa isolates in Taiwan revealed a trend toward prominent escalation in the annual non-susceptible (NS) rates to anti-pseudomonal carbapenems (from 19.7% in 2016 to 27.5% in 2018 [ Figure 1 ]; 95% CI: 0.545–0.936; P = 0.016) ( Jean et al., 2021 ). When assessed using linear regression analysis, these results corresponded with the annual proportions of pneumonia-causing P. aeruginosa isolates ( r = 0.980, P = 0.127) ( Jean et al., 2021 ). An outbreak of XDR- P. aeruginosa infections was reported in a tertiary care pediatric hospital in Italy between 2011 and 2012 ( Ciofi Degli Atti et al., 2014 ).…”

Section: Global Trends Of Carbapenem Resistance Among Important Gnb S...mentioning

confidence: 99%

“…Among other potential novel antibiotics, ceftolozane-tazobactam was inactive against isolates of CPE isolates, several AmpC-producing Enterobacterales, and most ESBL-producing K. pneumoniae ( Jean et al., 2021 ). Cefepime in combination with enmetazobactam (formerly AAI101, a β-lactamase inhibitor that structurally comprises penicillanic acid sulfone), exhibited lower MICs against isolates of ESBL-producing Enterobacterales and KPC-producing E. coli than CP- K. pneumoniae ( Morrissey et al., 2019 ; Papp-Wallace et al., 2019 ; Jean et al., 2022 ).…”

Section: Antibiotic Treatment Against Cr- or Xdr-gnbmentioning

confidence: 99%

“…De-escalation of antibiotics into a single agent is strongly recommended when susceptibility of the implicated GNB (including MDR/XDR- P. aeruginosa ) isolate is known, and there is a significant improvement in the patient’s condition ( Boyd and Nailor, 2011 ). Among the novel antibiotics that have been launched to combat MDR-GNB isolates, ceftolozane-tazobactam has excellent in vitro activity against global CR- and XDR- P. aeruginosa strains, including those with overexpression of efflux pumps but no carbapenemase production ( Hong et al., 2013 ; Jean et al., 2021 ). Despite not being validated by several randomized clinical studies, ceftazidime-avibactam ( Sader et al., 2017b ; Kuo et al., 2021 ), cefepime-zidebactam ( Sader et al., 2017a ; Kuo et al., 2021 ; Jean et al., 2022 ), cefiderocol ( Hsueh et al., 2019 ; Yamano, 2019 ; Bassetti et al., 2021 ; Liu et al., 2021 ), imipenem-relebactam (showing excellent in vitro activity relative to imipenem solely against OprD-losing P. aeruginosa isolates with Pseudomonas -derived cephalosporinase hyper-production) ( Tselepis et al., 2020 ; Kuo et al., 2021 ), meropenem-vaborbactam ( Novelli et al., 2020 ; Kuo et al., 2021 ), meropenem-nacubactam ( Asempa et al., 2020 ), and cefepime-taniborbactam ( Wang X. et al., 2020 ) are considered as promising alternatives against infections caused by CR- or MDR- P. aeruginosa isolates.…”

Section: Antibiotic Treatment Against Cr- or Xdr-gnbmentioning

confidence: 99%

“…If two in vitro active agents are not available, in vitro synergy studies are valuable in choosing the most appropriate targeted combination scheme ( Piperaki et al., 2019 ). Novel antibiotics, including ceftolozane-tazobactam, imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam, aztreonam-avibactam, cefepime-enmetazobactam, and cefepime-zidebactam, have significantly poor in vitro activity against XDR- A. baumannii complex, while exhibiting excellent in vitro efficacy against CRE or CR- P. aeruginosa ( Biedenbach et al., 2015 ; Livermore et al., 2017 ; Sader et al., 2017a ; Groft et al., 2021 ; Jean et al., 2021 ; Liu et al., 2021 ; Zhang et al., 2021a ). In contrast, cefiderocol, a novel siderophore modified from ceftazidime, exhibited excellent in vitro activity against several carbapenem-NS GNB species, including A. baumannii complex ( Hsueh et al., 2019 ); however, compared to the best available therapy, higher all-cause mortality rates were observed during the early hospitalization course when cefiderocol was administered for the treatment of patients with nosocomial pneumonia and BSI caused by CR- Acinetobacter species ( Bassetti et al., 2021 ).…”

Section: Antibiotic Treatment Against Cr- or Xdr-gnbmentioning

confidence: 99%

See 4 more Smart Citations

Global Threat of Carbapenem-Resistant Gram-Negative Bacteria

Jean

Harnod

Hsueh

2022

Front. Cell. Infect. Microbiol.

Self Cite

140

View full text Add to dashboard Cite

Infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria (GNB), including carbapenem-resistant (CR) Enterobacterales (CRE; harboring mainly blaKPC, blaNDM, and blaOXA-48-like genes), CR- or MDR/XDR-Pseudomonas aeruginosa (production of VIM, IMP, or NDM carbapenemases combined with porin alteration), and Acinetobacter baumannii complex (producing mainly OXA-23, OXA-58-like carbapenemases), have gradually worsened and become a major challenge to public health because of limited antibiotic choice and high case-fatality rates. Diverse MDR/XDR-GNB isolates have been predominantly cultured from inpatients and hospital equipment/settings, but CRE has also been identified in community settings and long-term care facilities. Several CRE outbreaks cost hospitals and healthcare institutions huge economic burdens for disinfection and containment of their disseminations. Parenteral polymyxin B/E has been observed to have a poor pharmacokinetic profile for the treatment of CR- and XDR-GNB. It has been determined that tigecycline is suitable for the treatment of bloodstream infections owing to GNB, with a minimum inhibitory concentration of ≤ 0.5 mg/L. Ceftazidime-avibactam is a last-resort antibiotic against GNB of Ambler class A/C/D enzyme-producers and a majority of CR-P. aeruginosa isolates. Furthermore, ceftolozane-tazobactam is shown to exhibit excellent in vitro activity against CR- and XDR-P. aeruginosa isolates. Several pharmaceuticals have devoted to exploring novel antibiotics to combat these troublesome XDR-GNBs. Nevertheless, only few antibiotics are shown to be effective in vitro against CR/XDR-A. baumannii complex isolates. In this era of antibiotic pipelines, strict implementation of antibiotic stewardship is as important as in-time isolation cohorts in limiting the spread of CR/XDR-GNB and alleviating the worsening trends of resistance.

show abstract

Section: Global Trends Of Carbapenem Resistance Among Important Gnb S...mentioning

confidence: 99%

Section: Global Trends Of Carbapenem Resistance Among Important Gnb S...mentioning

confidence: 99%

Section: Antibiotic Treatment Against Cr- or Xdr-gnbmentioning

confidence: 99%

Section: Antibiotic Treatment Against Cr- or Xdr-gnbmentioning

confidence: 99%

Section: Antibiotic Treatment Against Cr- or Xdr-gnbmentioning

confidence: 99%

See 3 more Smart Citations

Global Threat of Carbapenem-Resistant Gram-Negative Bacteria

Jean

Harnod

Hsueh

2022

Front. Cell. Infect. Microbiol.

Self Cite

140

View full text Add to dashboard Cite

show abstract

New advances in management and treatment of cardiac implantable electronic devices infections

Russo,

Serraino,

Serapide

et al. 2023

Infection

View full text Add to dashboard Cite

Cardiac implantable electronic devices (CIED) are increasingly used worldwide, and infection of these devices remains one of the most feared complications.CIED infections (CDIs) represent a challenge for physicians and the healthcare system in general as they require prolonged hospitalization and antibiotic treatment and are burdened by high mortality and high costs, so management of CDIs must be multidisciplinary.The exact incidence of CDIs is difficult to define, considering that it is influenced by various factors mainly represented by the implanted device and the type of procedure. Risk factors for CDIs could be divided into three categories: device related, patient related, and procedural related and the etiology is mainly sustained by Gram-positive bacteria; however, other etiologies cannot be underestimated. As a matter of fact, the two cornerstones in the treatment of these infections are device removal and antimicrobial treatment. Finally, therapeutic drug monitoring and PK/PD correlations should be encouraged in all patients with CDIs receiving antibiotic therapy and may result in a better clinical outcome and a reduction in antibiotic resistance and economic costs.In this narrative review, we look at what is new in the management of these difficult-to-treat infections.

show abstract

Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019

Jean

et al. 2022

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018

Cited by 35 publications

References 43 publications

Global Threat of Carbapenem-Resistant Gram-Negative Bacteria

Global Threat of Carbapenem-Resistant Gram-Negative Bacteria

New advances in management and treatment of cardiac implantable electronic devices infections

Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019

Contact Info

Product

Resources

About